Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
One Percent Rule Checklist For Safer Forex Trading Risk 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Bristol Myers Squibb Co would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments and shield itself from competition posed by Merck & Co’s Keytruda on its for its cancer immunotherapy, Opdivo.
The deal gives Bristol Myers, which acquired pharmaceutical company Celgene last year for $74 billion, access to Myokardia’s lead heart drug candidate with blockbuster potential, mavacamten.
According to David Nierengarten, a Wedbush analyst, mavacamten is expected to be a “multi-billion dollar asset” as sales estimates for the treatment of obstructive hypertrophic cardiomyopathy (HCM) is expected to reach about $2.5 billion by 2026.
Hypertrophic cardiomyopathy is estimated to affect one in every 500 people globally.
MyoKardia expects to submit a marketing application to the US health regulator for mavacamten as an obstructive HCM treatment in the first quarter of 2021.
Bristol Myers' portfolio of heart drugs includes blood thinner Eliquis, which made up about 21 percent of the company’s total sales in its latest reported quarter.
